Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T17:32:02.917Z Has data issue: false hasContentIssue false
  • English
  • Français

Growth Hormone Response to Clonidine in Obsessive-Compulsive Patients

Published online by Cambridge University Press:  29 January 2018

Larry J. Siever ,
Thomas R. Insel ,
David C. Jimerson ,
C. Raymond Lake ,
Thomas W. Uhde ,
Joseph Aloi  and
Dennis L. Murphy
Larry J. Siever
Affiliation:
National Institute of Mental Health, Bethesda, Maryland 20205, USA
Thomas R. Insel
Affiliation:
National Institute of Mental Health
David C. Jimerson
Affiliation:
National Institute of Mental Health
C. Raymond Lake
Affiliation:
University of the Health Services, Bethesda, Maryland 20014, USA
Thomas W. Uhde
Affiliation:
Biologic Psychiatry Branch, National Institute of Mental Health
Joseph Aloi
Affiliation:
National Institute of Mental Health
Dennis L. Murphy
Affiliation:
National Institute of Mental Health
Get access Rights & Permissions [Opens in a new window]

Summary

We have observed a lesser growth hormone response to intravenous clonidine administration in nine obsessive-compulsive disorder patients meeting research diagnostic criteria than in nine matched controls. The obsessive-compulsive disorder patients had higher plasma free 3-methoxy-4-hydroxyphenylglycol and plasma norepinephrine levels before clonidine than the controls. As blunted growth hormone responses to clonidine are also characteristic of affective disorder patients, these results support other observations of a psychobiologic affinity between these two groups and are also compatible with an association between increased presynaptic noradrenergic activity and decreased post-synaptic receptor responsiveness.

Type
Papers
Information
The British Journal of Psychiatry , Volume 142 , Issue 2 , February 1983 , pp. 184 - 187
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Charney, D. S., Heninger, G. R. & Sternberg, D. E. (1983) Failure of chronic antidepressant treatment to alter growth hormone response to clonidine. Psychiatry Research, in press.Google Scholar
Charney, D. S., Heninger, G. R., Sternberg, D. E., Hafstad, K. M., Griddings, S. & Landis, D. H. (1982) Adrenergic receptor sensitivity in depressive illness. Archives of General Psychiatry, 39, 290–4.Google Scholar
Checkley, S. A., Slade, A. P. & Shur, E. (1981) Growth hormone and other responses to clonidine in patients with endogenous depression. British Journal of Psychiatry, 138, 51–5.CrossRefGoogle ScholarPubMed
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–96.Google Scholar
Insel, T. R., Alterman, I., Cohen, R. M., Hamilton, J., Gillin, J. C., Buchsbaum, M. S., Zann, T. & Murphy, D. L. (1982a) Psychobiologic studies of obsessional disorder. New Research Abstracts of the American Psychiatric Association, NR 70. Washington, DC: APA.Google Scholar
Insel, T. R., Kalin, N. H., Guttmacher, L. P., Cohen, R. M. & Murphy, D. L. (1982b) The dexamethasone suppression test in patients with primary obsessive-compulsive disorder. Psychiatric Research, 6, 153–60.Google Scholar
Insel, T. R., Gillin, J. C., Moore, A., Lowenstein, R., Murphy, D. L. & Mendelson, W. B. The sleep of obsessive-compulsive disorder patients. Archives of General Psychiatry, (in press).Google Scholar
Jimerson, D. C., Markey, S. P., Oliver, J. A. & Kopin, I. J. (1981) Simultaneous measurement of plasma 4-hydroxy-3-methoxyphenylethylene glycol and 3,4-dihydroxyphenylethylene glycol by gas chromatographymass spectrometry. Biomedical Mass Spectrometry, 8, 256–9.Google Scholar
Lake, C. R., Ziegler, M. G. & Kopin, I. J. (1976) Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Science, 18, 1315–26.Google Scholar
Marks, I. M., Stern, R., Mawson, D. J., Cobb, J. & McDonald, R. (1980) Clomipramine and exposure for obsessive-compulsive rituals: 1. British Journal of Psychiatry, 136, 1–25.Google Scholar
Martin, J. B., Reichlin, S. & Brown, G. M. (1977) Clinical Neuroendocrinology, pp 165–9. Philadelphia: F. A. Davis.Google ScholarPubMed
Matussek, N., Ackenheil, M. & Hippius, H. et al. (1980) Effect of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Research, 2, 25–36.CrossRefGoogle ScholarPubMed
Siever, L. J., Insel, T. R. & Uhde, T. (1981) Noradrenergic challenges in the affective disorders. Journal of Clinical Psychopharmacology, 1, 193–206.CrossRefGoogle ScholarPubMed
Siever, L. J., Uhde, T. W., Insel, T. R., Roy, B. F. & Murphy, D. L. (1982a) Growth hormone response to clonidine unchanged by chronic clorgyline treatment. Psychiatry Research, 7, 139–44.Google Scholar
Siever, L. J., Uhde, T. W., Silberman, E. K., Jimerson, D. C., Aloi, J. A., Post, R. M. & Murphy, D. L. (1982b) The growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls. Psychiatry Research, 6, 171–83.CrossRefGoogle ScholarPubMed
Siever, L. J., Uhde, T. W., Potter, W. Z. & Murphy, D. L. (in press) Norepinephrine in the affective disorders: II. Receptor assessment strategies. In Norepinephrine: Clinical Aspects, (eds. Lake, C. R. and Ziegler, M. G.). Baltimore: Williams and Wilkins.Google Scholar
Thoren, B., Asberg, M., Cronholm, B., Jornestedt, L. & Traskman, L. (1980) Clomipramine treatment of obsessive compulsive disorder: A controlled clinical trial. Archives of General Psychiatry, 37, 1281–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.